Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071435
Filing Date
2025-05-14
Accepted
2025-05-14 16:18:00
Documents
123
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atai-20250331.htm   iXBRL 10-Q 3485579
2 EX-31.1 atai-ex31_1.htm EX-31.1 16080
3 EX-31.2 atai-ex31_2.htm EX-31.2 17445
4 EX-32.1 atai-ex32_1.htm EX-32.1 10103
5 EX-32.2 atai-ex32_2.htm EX-32.2 9960
6 GRAPHIC img107785748_0.jpg GRAPHIC 38996
  Complete submission text file 0000950170-25-071435.txt   18906160

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atai-20250331.xsd EX-101.SCH 3570054
126 EXTRACTED XBRL INSTANCE DOCUMENT atai-20250331_htm.xml XML 3559072
Mailing Address WALLSTRASSE 16 BERLIN 2M 10179
Business Address WALLSTRASSE 16 BERLIN 2M 10179 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40493 | Film No.: 25945822
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)